EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

C5a receptor inhibition and minimal steroids for induction of remission in ANCA-associated vasculitis

Azm Ul Hussain iD, Catherine King, Jed Ashman, Joseph Sturman iD, Helen De Takats, Nadya Wall iD, Charlotte Talbot, Adam Cunningham, Paul Moss, Kashif Eqbal, Lisha McClelland, Anjali Crawshaw und 4 weitere

Nephrology Dialysis Transplantation · 12.11.2026

DOI: 10.1093/ndt/gfag262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 12.11.2026. Verfasst von Azm Ul Hussain und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis C5a receptor (C5aR) inhibition with avacopan has enabled cumulative glucocorticoid (GC) dose reduction in ANCA-associated vasculitis (AAV); however, real-world steroid use remains high. This study evaluates a minimal-GC plus avacopan-based regimen against standard-of-care GC for clinical efficacy, renal recovery, urinary biomarkers, and patient-reported outcomes (AAV-PRO). We hypothesised that this regimen would permit substantial GC reduction while maintaining clinical disease control and renal recovery.

Methods

This two-centre retrospective study included 126 patients with newly diagnosed or relapsing AAV (70 avacopan; 56 GC). The avacopan group followed the minimal-GC plus avacopan-based regimen: prednisolone 30 mg daily for one week, then 20 mg for one week, with no protocolised upfront intravenous methylprednisolone; the GC group received a standard high-dose oral GC taper (from 1 mg/kg, capped at 60 mg/day). Both received standard induction with rituximab or cyclophosphamide. Outcomes included 12-month sustained remission, eGFR change, safety, AAV-PRO scores, and urinary sCD163, MCP-1 and C5a trajectories.

Results

Baseline characteristics were comparable, with median presenting eGFR 23 versus 25 mL/min/1.73 m² (P = 0.31). Median 12-month cumulative prednisolone was 390 mg with avacopan versus 3535 mg with GC (P < 0.001). Observed sustained remission was 93% versus 91% (P = 0.75) and relapse 6% versus 11% (P = 0.30). Median eGFR increase was 20 versus 18 mL/min/1.73 m² (P = 0.32), with no significant difference among those presenting with eGFR < 15 (P = 0.20). Severe infection rates did not differ significantly (6% versus 9%). AAV-PRO scores were significantly lower with avacopan (median 97 versus 197; P = 0.04). No significant between-group difference in biomarker trajectories was detected.

Conclusions

In this observational cohort, the minimal-GC plus avacopan-based regimen showed no statistically significant differences in clinical or renal outcomes versus high-dose steroids while reducing cumulative GC exposure by ∼90%. These real-world observations support the feasibility of substantial upfront GC minimisation but should be regarded as supportive rather than confirmatory.

Schlagwörter

Stichwörter der Autor:innen

ANCA-associated vasculitisavacopaneGFRglucocorticoidsurinary biomarkers

Autor:innen und Institutionen

  • Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Northwick Park Hospital, London, UK.
  • Department of Renal Medicine, The Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, UK.
  • New Cross Hospital, The Royal Wolverhampton NHS Foundation Trust, Wolverhampton, UK.
  • Department of Renal Medicine, Birmingham Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

ORCID-Profile: Azm Ul Hussain, Joseph Sturman, Nadya Wall, Benjamin Rhodes, Lorraine Harper, Dimitrios Chanouzas

Zitieren

APA

Hussain, A. U., King, C., Ashman, J., Sturman, J., De Takats, H., Wall, N., Talbot, C., Cunningham, A., Moss, P., Eqbal, K., McClelland, L., Crawshaw, A., Rhodes, B., Wessels, J., Harper, L., & Chanouzas, D. (2026). C5a receptor inhibition and minimal steroids for induction of remission in ANCA-associated vasculitis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag262

Vancouver

Hussain AU, King C, Ashman J, Sturman J, De Takats H, Wall N, et al. C5a receptor inhibition and minimal steroids for induction of remission in ANCA-associated vasculitis. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag262

BibTeX
@article{Hussain2026,
  author = {Hussain, Azm Ul and King, Catherine and Ashman, Jed and Sturman, Joseph and De Takats, Helen and Wall, Nadya and Talbot, Charlotte and Cunningham, Adam and Moss, Paul and Eqbal, Kashif and McClelland, Lisha and Crawshaw, Anjali and Rhodes, Benjamin and Wessels, Julie and Harper, Lorraine and Chanouzas, Dimitrios},
  title = {C5a receptor inhibition and minimal steroids for induction of remission in ANCA-associated vasculitis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag262}
}
Kostenlos starten →